Business Context and Reporting Period
Company: X4 Pharmaceuticals, Inc. (XFOR)
Filing Type: Form 8-K (Current Report)
Date of Report: June 27, 2019
Event: Entry into a Material Definitive Agreement (Amended and Restated Loan and Security Agreement) with Hercules Capital, Inc.
Key Financial Metrics and Debt Structure
This filing details a new financing arrangement rather than reporting operational financial results (revenue, profit, or cash flow from operations are not provided in this document).
- Total Credit Facility: Up to $35.0 million aggregate maximum borrowings.
- Tranche 1 Term Loan: Up to $25.0 million (includes $10.0 million conversion of prior debt). $20.0 million borrowed on closing (June 27, 2019), with up to $5.0 million available through December 15, 2020.
- Tranche 2 Term Loan: Up to $10.0 million available through June 15, 2022, subject to lender approval.
- Interest Rate: Variable rate equal to the greater of 8.75% or 8.75% plus (WSJ Prime Rate minus 6.0%). Increases by 4.0% upon default.
- Repayment Terms: Interest-only payments through January 1, 2022; principal and interest from February 1, 2022, to maturity on July 1, 2023.
- Collateral: Substantially all personal property and assets, excluding intellectual property (though rights to proceeds from IP are included).
Material Changes and Fees
The company amended its existing loan agreement to increase borrowing capacity and restructure terms.
- Conversion Balance: $10.0 million of the new facility converts debt from the October 2018 Original Loan Agreement.
- Upfront Fees: $795,000 payable regarding the conversion balance (due by November 1, 2021 or full repayment).
- Commitment Fees: 4.0% of aggregate principal advances (up to $1.4 million if fully drawn), payable at maturity or full repayment.
- Prepayment Penalty: Up to 2.0% of the principal amount outstanding if prepaid.
Covenants, Risks, and Management Commentary
The agreement imposes strict financial and operational covenants:
- Liquidity Covenant: Must maintain minimum liquidity equal to the lesser of 125% of outstanding borrowings or 100% of cash equivalents (excluding up to $2.5 million held by an Excluded Subsidiary).
- Restrictions: Limits on incurring additional indebtedness, paying dividends, encumbering intellectual property, or engaging in mergers/acquisitions.
- Equity Participation: Hercules Capital has the right to participate in future equity offerings for financing purposes up to $2.0 million in the aggregate.
- Events of Default: Include payment default, insolvency, or material adverse change in business/financial condition, triggering acceleration of obligations.
Investor Verification Checklist
- Verify the company's current cash balance to ensure compliance with the 125% liquidity covenant relative to the $20.0 million drawn.
- Confirm the status of the $10.0 million Tranche 2 availability and any conditions required for approval.
- Review the impact of the 4.0% commitment fee on future cash flow upon maturity.
- Assess the risk of the 4.0% interest rate penalty in the event of a covenant breach or default.
- Monitor future equity offerings for potential dilution due to Hercules Capital's $2.0 million participation right.